What is Lifesci Capital’s Forecast for VERA Q2 Earnings?

Vera Therapeutics, Inc. (NASDAQ:VERA) – Investment analysts at Lifesci Capital issued their Q2 2025 earnings per share estimates for Vera Therapeutics in a report released on Monday, June 2nd. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings of ($0.82) per share for the quarter. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for Vera Therapeutics’ Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.85) EPS and FY2025 earnings at ($3.32) EPS.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the prior year, the business posted ($0.56) earnings per share.

Several other research firms have also weighed in on VERA. JPMorgan Chase & Co. reduced their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th. Guggenheim increased their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. HC Wainwright raised their target price on shares of Vera Therapeutics from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Monday. Scotiabank lifted their price target on shares of Vera Therapeutics from $55.00 to $65.00 and gave the stock a “sector outperform” rating in a research report on Monday. Finally, Cantor Fitzgerald cut their price objective on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $65.00.

Vera Therapeutics Trading Down 2.6%

Shares of Vera Therapeutics stock opened at $30.91 on Tuesday. The business has a fifty day simple moving average of $22.15 and a 200-day simple moving average of $31.86. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -11.84 and a beta of 1.28. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Institutional Investors Weigh In On Vera Therapeutics

A number of large investors have recently made changes to their positions in the company. Huntington National Bank purchased a new position in Vera Therapeutics during the 4th quarter worth approximately $26,000. AlphaQuest LLC acquired a new stake in shares of Vera Therapeutics in the fourth quarter worth $34,000. GF Fund Management CO. LTD. purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at $56,000. Quarry LP raised its position in Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after buying an additional 500 shares during the period. Finally, KBC Group NV lifted its stake in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.